Position in CELC
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$345,758,951
-$1,183,389 QoQ
Shares Held
3,304,903
+8.7% QoQ
Ownership
6.75%
of shares outstanding
% of Portfolio
2.95%
of 13F equity value
Holder Rank
#3
of 274 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RTW INVESTMENTS, LP holds $9,530,420,260 across 63 Biotechnology names. CELC ranks #9 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
1,993,687 | $1,070,510,234 | |
| 2 | ARGX |
Argenx SE
|
709,446 | $658,202,715 | |
| 3 | PTCT |
Ptc Therapeutics, Inc.
|
7,746,415 | $631,875,071 | |
| 4 | PTGX |
Protagonist Therapeutics, Inc
|
5,061,175 | $620,398,831 | |
| 5 | CGON |
CG Oncology, Inc.
|
8,514,590 | $604,961,619 | |
| 6 | INSM |
INSMED Inc
|
4,842,880 | $516,347,865 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
13,900,620 | $434,533,381 | |
| 8 | SYRE |
Spyre Therapeutics, Inc.
|
4,251,996 | $377,492,204 |
All Filings in CELC
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $345,758,951 | 3,304,903 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $346,942,340 | 3,039,621 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $54,872,958 | 550,160 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||